Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis
Status:
Unknown status
Trial end date:
2021-10-04
Target enrollment:
Participant gender:
Summary
The incidence of intra-abdominal candidiasis is increasing, and it is now the leading
indication for antifungal therapy, ahead of candidemia. Prospective randomized trials of
antifungal therapy have almost exclusively concerned patients with candidemia and did not
include patients with intra-abdominal infections. The aim of this study is to demonstrate
that caspofungin antifungal therapy for intra-abdominal candidiasis in ICU patients is
associated with lower failure rate compared to placebo.